neuropathy semaglutide Wegovy may raise risk of ischemic optic 👁️ The obesity drug semaglutide, marketed as Wegovy, was associated with a significantly higher risk of ischemic optic neuropathy than the diabetes formulation Ozempic fda safety communication semaglutide naion

doi: 10.1016/j.ecl.2013.07.002 [PubMed] 26696689 American Diabetes Association

During our previous investigation into the role of GSNOR in age-related learning and memory 29 , we unexpectedly observed that after middle age, there is no significant body weight increasing in GSNOR knockout (KO) mice, as usually increasing in wild-type (WT) controls

However, repeated room temperature exposure has a cumulative effect

Wegovy is registered specifically for weight management in people with obesity or weight-related medical conditions

Approval came the next day through the patient portal, the prescription shipped the same day it was approved, and the package arrived the following morning via overnight FedExtwo full days